+ Watch BTX
on My Watchlist
What does BioTime do these days? Renevia? PanDaTox? PanC-Dx? Hystem-based surgical products? It's anyone's guess what management will choose to tout at the quarterly CC, but it's a safe bet there won't be a mention of whatever the centerpiece was at the last CC. BioTime management just loves to hoard disparate junk and bust out with the occasional wild PR when they need to raise some dilutive cash. 4 is the share price where I figure BioTime's poor long-term prospects outweigh the possibility of an irrational PR-based spike.
give back time
Short. Biotech. Revs down slightly. Losses widening.
Like all early-stage biotechs, BioTime's success relies not on its ability to develop novel treatments, but to get them through clinical trial and regulatory testing. BTX isn't setup for that - so my assumption is that they demonstrate high potential with their adult-based stem cell lines, and sell the technology out. Still, be prepared for a loooooong wait.
Very long term investment
Dr. West. CEO
This company has a market cap of less than $400 M and a pipeline of product candidates that, if successful, could easily generate sales in the hundreds of millions or even billions. The industry average P/S multiple for pharma & biotech is 3.31. If the company develops one successful $1B candidate and is bought out for half the average multiple, then you have at least a 3-bagger even after dilution.
Regen medician is going to sci rocket if this stuff will by pass the big farma and fda money makers. BTIM
Innovative and creative company that can change medicine as we know it
Biotime has Dr Michael West as its CEOBiotime primary growth machine is going to be Stem cell related products and assays.Stem cell industry has the following major issues.1. Purity.2. Scalability3. HistocompatibilityHistocompatibility is basically the rejection issues that are faced when there is an organ transplant. Even at the stem cell level the body can identify foreign bodies(stem cells) and will try and destroy them. iPS (induced Pluripotent Stem cell) is the technology which overcomes this problem.The patients skin cells have stem cells (that is why the skin can regenerate) BTIM has a process in place to convert skin stem cells into the generic "like" embryonic stem cell process and this process is vector (virus) free process and called iPS2. Scalability issues has been dealt with ACTCellerate growth process of growing stem cells in a growth medium3. Purity issues have been resolved by using shot gun cloning. ie the required stem cell is selected from the more than 140 different types of stem cells and the selected stem cell is then grown and since it is selected/purified before growth/cloning the cells are 100% of the required type.Company is one step ahead of the industry and hence delay in recognition.. get in now and this is a long term play on the future of medicine (your own body can provide the medicine -skin graft which can cure all your ills.)VERY VERY STRONG BUY!!! MULTI-BAGGER for sure!!http://whatsup-stockideas.blogspot.com=happy investing
Read Tasty's comment.
Stock is in an explosive stem cell industry and has demonstrated trial results and studies that surpass all others in this space.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions